COMP <GO>
CVS vs KOF // REVENUE GROWTH (YOY)
CVS Health Corporation (NYSE) VS. Coca Cola Femsa S.A.B. de C.V. American (NYSE) • 15-METRIC TALLY: CVS 4
— KOF 8
▲ REVENUE GROWTH (YOY) LEADER: CVS
LAST: $90.25 (-0.09%) • MKT CAP: $115.53B
revenue-growth
7.80%
LAST: $115.68 (+0.16%) • MKT CAP: $194.12B
revenue-growth
3.30%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CVS VS. KOF)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CVS | KOF | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 45.00% | 41.00% | +4.00 | CVS | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 2.60% | 9.90% | -7.30 | KOF | /roic <GO> |
| EV/EBITDA & P/E Valuation | 25.7x | 21.0x | +4.70 | KOF | /valuation <GO> |
| Free Cash Flow Yield | 6.76% | 2.21% | +4.55 | CVS | /fcf-yield <GO> |
| Operating Margin | 1.20% | 13.90% | -12.70 | KOF | /operating-margins <GO> |
| Net Profit Margin | 0.40% | 10.90% | -10.50 | KOF | /net-margins <GO> |
| Revenue Growth (YoY) ACTIVE | 7.80% | 3.30% | +4.50 | CVS | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 2.94% | 0.00% | +2.94 | CVS | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.31 | 3.74 | -1.43 | KOF | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 7/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.50% | 6.50% | 0.00 | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 47.5 | 54.9 | -7.36 | KOF | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.88 | 0.88 | 0.00 | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 60.7x | 30.5x | +30.20 | KOF | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $115.53B | $194.12B | -$78.59B | KOF | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CVS REV | KOF REV | CVS GROSS % | KOF GROSS % | CVS FCF | KOF FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $402.07B | — | 45.0% | — | $7.81B | — |
| FY 2024 | $372.81B | — | 44.7% | — | $6.33B | — |
| FY 2023 | $357.78B | — | 44.0% | — | -$2.67B | — |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CVS // BETA 0.88
KOF // BETA 0.88